Browsing Tag
Amicus Therapeutics
2 posts
Dimerix (ASX: DXB) buys Phase 2-ready DMX-652 in deal worth up to $292m
Dimerix buys Phase 2-ready DMX-652 for US$5 million upfront, widening its kidney pipeline while taking on milestones, royalties and execution risk ahead.
BioMarin’s BMN 401 setback raises regulatory questions after ENPP1 deficiency trial meets only one endpoint
BioMarin moved the biomarker, not the rickets score. BMN 401 now tests how much regulators will accept in ultra-rare disease trials.